Lifeward acquires Oramed's POD tech; Oramed gets up to 49.99% LFWD stake; up to $47M capital

Lifeward Ltd.

Issues Oramed shares & pre-funded warrants for 49.99% fully diluted equity (max 45% post-closing).
Up to $47M from Oramed & another investor via $20M convertible notes (8% interest, 100% warrant coverage) and equity.
Oramed to receive 4% of ReWalk net sales for up to 10 yrs; board expands to 6 (2 each from LFWD, Oramed, 2 external).
Oramed funds/manages POD clinical program; $10M note funded at close, second $10M conditional on revenue or share price milestone.
Transaction subject to shareholder approval; 120-day lock-up for officers, directors, and Oramed shares.

item 1.01item 2.03item 3.02item 5.02item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.